Company profile
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc.

Pipeline2 assets

  • bemnifosbuvir/ruzasvir fixed-dose combinationBEM/RZR / HCV NS5B polymerase; HCV NS5A / oral small-molecule antiviral regimen / viral hepatitis
    hepatitis C virus (HCV) infectionPhase 3activeglobal
  • AT-587AT-587 / hepatitis E virus (HEV) / oral nucleotide analog / viral hepatitis
    chronic hepatitis E virus (HEV) infection in immunocompromised patientspreclinicalPhase 1 anticipated mid-2026

Latest news10 items

All news

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting Antiviral for the Treatment of Hepatitis E Virus BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc.

Presentation / Abstract • Phase 1EASL abstract release Thu, May 28, 2026, 8:30 AM CEST

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been

Presentation / AbstractEASL abstract release Wed, May 13, 2026, 8:00 AM CET